Literature DB >> 7636517

The prevalence and prophylaxis of gout in England.

C M Harris1, D C Lloyd, J Lewis.   

Abstract

The prevalence of gout in England was reported as having nearly doubled in the 1970s to about 3 per 1000, and it is possible that it has continued to increase. There may also have been some change in the level of prophylactic therapy compared with the 44.8% recorded in 1979. In this study, data were provided from their morbidity registers by 40 volunteer practices with a combined population of over 300,000 patients. Analyses of prevalence by age and sex, and of the extent of prophylaxis were made. The male:female ratio and the increase with age found were in line with earlier work, but overall prevalence was much higher at almost 10 per 1000. There was considerable inter-practice variation: 20% of this could be accounted for by the age and sex structure of the practice populations, but neither economic status nor broad geographical factors appeared to be significant, and it did not appear to be due to variation between practices in the level of special interest in gout. Prophylactic therapy--almost entirely allopurinol--was being prescribed for 48% of the sufferers; though practices varied widely in their propensity to give it, as a group the amount of allopurinol they used was close to the national average. The increase found in the prevalence of gout may be related to an increase in obesity in the population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636517     DOI: 10.1016/0895-4356(94)00244-k

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  41 in total

Review 1.  The epidemiology of uric acid and fructose.

Authors:  Young Hee Rho; Yanyan Zhu; Hyon K Choi
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

Review 2.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

Review 3.  Recent advances in the epidemiology of gout.

Authors:  Kenneth G Saag; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

4.  Manifestations of metabolic syndrome associated with male gout in different age strata.

Authors:  Shih-Yang Chen; Ching-Lang Chen; Ming-Lai Shen
Journal:  Clin Rheumatol       Date:  2007-01-26       Impact factor: 2.980

5.  Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares?

Authors:  Angelo L Gaffo; Kenneth G Saag
Journal:  Nat Clin Pract Rheumatol       Date:  2008-12-02

Review 6.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

7.  The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.

Authors:  Sharan K Rai; J Antonio Aviña-Zubieta; Natalie McCormick; Mary A De Vera; Kam Shojania; Eric C Sayre; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2016-08-17       Impact factor: 5.532

Review 8.  Determinants of the prevalence of gout in the general population: a systematic review and meta-regression.

Authors:  José M A Wijnands; Wolfgang Viechtbauer; Kristof Thevissen; Ilja C W Arts; Pieter C Dagnelie; Coen D A Stehouwer; Sjef van der Linden; Annelies Boonen
Journal:  Eur J Epidemiol       Date:  2014-07-27       Impact factor: 8.082

9.  Morbidity and prescribing patterns for the middle-aged population of Scotland.

Authors:  F G Whitelaw; S L Nevin; R J Taylor; A H Watt
Journal:  Br J Gen Pract       Date:  1996-12       Impact factor: 5.386

Review 10.  Gout.

Authors:  Martin Underwood
Journal:  BMJ Clin Evid       Date:  2008-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.